Martin Egli and Muthiah Manoharan’s Review of Approved Oligonucleotide Therapeutics

May 25th, 2023|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

Martin Egli and Muthiah Manoharan recently co-wrote an outstanding review that is a great resource for anyone in our community. The review, titled “Chemistry, structure and function of approved oligonucleotide therapeutics,” is a collection of information about the eighteen nucleic acid therapeutics that have ...

Amazon Prime for DNA – Has A New Era of Oligonucleotide Synthesis Begun?

May 15th, 2023|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

Phosphoramidite chemistry has been used for decades to write synthetic DNA, but challenges arise when longer, more complex oligos are needed. After years of innovation fueled by the goal of meeting this need, Ansa Biotechnologies announced de novo synthesis of a 1005 base long oligonucleotide ...

An ASO Is Granted Accelerated Approval By the FDA

May 3rd, 2023|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

Tofersen, an antisense oligonucleotide treatment for SOD1-ALS, a rare form of amyotrophic lateral sclerosis (ALS), was recently granted accelerated approval by the U.S. FDA. This is quite significant, as approval was granted based on a biomarker rather than clear clinical improvement of the disease. ...

Introduction to Nucleic Acid Immunity, and It’s Implications For Optimizing Cancer Immunotherapy

April 26th, 2023|Categories: Past Webinars|

Time: 8AM PST | 11AM EST | 5PM CET Date: June 8, 2023 Starting from the concept and principles of Nucleic Acid Immunity, I will explain why TLR7 and TLR9 are unique among the nucleic acid immune sensing receptors for their ability to ...

Innovation, Versatile Gene Editing Technologies, and Patent Battles

April 24th, 2023|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

Last June, at a genome editing summit in Lisbon, following a much-anticipated presentation by Tessera Therapeutics about their new gene editing technology, an audience member asked a question that is now the basis of a patent dispute: how was it different from the prime ...

Can There Be International Agreement on How to Navigate the Future of Genome Editing?

April 5th, 2023|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

Our world is changing at an astonishingly rapid pace and, as described a few weeks ago, CRISPR is poised to become a major source of change in many fields, from medicine to animals to crops. With any new technology, but especially one that has ...

Go to Top